BioCryst down on halted Phase IIb

BCRX fell $1.58 (16%) to $8 on Tuesday after reporting that it voluntarily placed on hold a Phase IIb trial of

Read the full 211 word article

How to gain access

Continue reading with a
two-week free trial.